VOR
Vor Biopharma Inc.
Next earnings Aug 10, 2026 · consensus $-0.71 EPS
Last earnings +4.7% on 2026-01-12
$16.10
▲ +7.84%$16.10▲ +235.42%
over 1Y
L $4.80EODHDH $53.40
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.8%
1W+7.8%
1M+3.7%
3M+11.2%
YTD+38.3%
1Y+235.4%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 13 analysts
Buy
Pre-revenue clinical-stage biotech with negative equity, a $696M loss, and no Phase 3 readout until 1H 2027 — speculative binary bet.
Vor Bio is no longer the company it was a year ago. The May 2025 Restructuring Plan wound down ~99% of the workforce (154 employees) and abandoned the prior pipeline, and the company pivoted entirely to telitacicept, an in-licensed asset from RemeGen for autoimmune indications (gMG, SjD). This is effectively a new biotech wearing the old ticker, with one Phase 3 program and no commercial revenue. Per management, topline gMG Phase 3 data is not expected until 1H 2027, meaning there is no near-term fundamental catalyst — just cash burn against a binary readout.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$69.0M | -$93.4M | -$126M | -$121M | -$372M |
| Net income | -$68.9M | -$92.1M | -$118M | -$117M | -$696M |
| Diluted EPS | -$2.10 | -$2.33 | -$1.75 | -$34.03 | -$70.50 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$390M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-88.5%
FCF yield-18.3%
Quality & risk
ROIC (est.)—
Free cash flow-$144M
Total debt—
Net cash$396M
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY-60.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-06-12
Annual meeting vote results filed; routine governance outcome with no strategy change.
- 8-K Reg FD disclosure2026-06-08
Reg FD disclosure (likely conference/investor deck) on telitacicept programs.
- 10-Q Quarterly report2026-05-13
Q1'26 10-Q: cash funds ops into early 2029; telitacicept Phase 3 enrolling.
- S-3 Shelf registration (potential raise)2026-04-27
Annual meeting proxy; routine board/comp votes, no strategic shift signaled.
- DEF 14A Proxy statement2026-04-27
Annual meeting proxy; routine board/comp votes, no strategic shift signaled.
- 10-K Annual report2026-03-30
FY25 net loss $696M from RemeGen license charge; pivot to telitacicept; $455M cash.
- 8-K Material agreement2026-03-27
2026 private placement priced; equity issuance extends cash runway to early 2029.
- S-3 Shelf registration (potential raise)2026-01-29
Shelf registration filed to facilitate future equity/debt issuance.
- 8-K Earnings results2026-01-12
Business update / preliminary results disclosure ahead of full year-end reporting.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-082026-06-08open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is Vor Biopharma Inc. (VOR) a buy?
- VOR currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue clinical-stage biotech with negative equity, a $696M loss, and no Phase 3 readout until 1H 2027 — speculative binary bet.
- What is Vor Biopharma Inc.'s quality score?
- VOR scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001817229, latest 10-Q filed 2026-05-13) · EODHD · analysis by claude-code · as of 6/25/2026, 2:59:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.